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Abstract
Objective: To investigate the association of dietary
pattern and mortality in international data.
Design: Cohort study with 20 years’ follow up of
mortality.
Setting: Five cohorts in Finland, the Netherlands, and
Italy.
Subjects: Population based random sample of 3045
men aged 50›70 years in 1970.
Main outcome measures: Food intake was estimated
using a cross check dietary history. In this dietary
survey method, the usual food consumption pattern
in the 6›12 months is estimated. A healthy diet
indicator was calculated for the dietary pattern, using
the World Health Organisation’s guidelines for the
prevention of chronic diseases. Vital status was
verified after 20 years of follow up, and death rates
were calculated.
Results: Dietary intake varied greatly in 1970 between
the three countries. In Finland and the Netherlands
the intake of saturated fatty acids and cholesterol was
high and the intake of alcohol was low; in Italy the
opposite was observed. In total 1796 men (59%) died
during 20 years of follow up. The healthy diet
indicator was inversely associated with mortality (P for
trend < 0.05). After adjustment for age, smoking, and
alcohol consumption, the relative risk in the group
with the healthiest diet indicator compared with the
group with the least healthy was 0.87 (95% confidence
interval 0.77 to 0.98). Estimated relative risks were
essentially similar within each country.
Conclusions: Dietary intake of men aged 50›70 is
associated with a 20 year, all cause mortality in
different cultures. The healthy diet indicator is useful
in evaluating the relation of mortality to dietary
patterns.
Introduction
Selected nutrients or food groups have often been
studied in relation to mortality,1›5 but studying dietary
patterns in relation to mortality has several advantages.
Using dietary patterns takes into account the high
intercorrelation of nutrients within the diet, which is
due to the choice of foods in which these nutrients
occur or to the consumption of a particular food at the
expense of another one.6 Also, studying dietary
patterns in relation to mortality provides a practical
way to evaluate the health effects of adherence to
dietary guidelines by individuals.7 It can help to identify
groups with an unhealthy dietary pattern and disclose
possibilities for prevention of chronic diseases or
disability.
To our knowledge, dietary pattern has been used to
study the association with mortality only within
individual countries.7›10 We developed a healthy diet
indicator, based on the World Health Organisation’s
dietary recommendations for the prevention of
chronic diseases,11 and investigated its association with
all cause mortality during 20 years of follow up in
population based samples from three different
countries (Finland, Italy, and the Netherlands).
Methods
Population
From 1958 to 1964, 16 population samples of men
aged 40›59 years from seven countries were enrolled
and examined at baseline for the seven countries
study.12 Since 1984, Finland, Italy, and the Netherlands
have continued the examination of their cohorts,
focusing on health and its determinants in elderly
people. The population has been described in detail.13
The participating cohorts were eastern and western
Finland; Crevalcore and Montegiorgio, Italy; and
Zutphen, the Netherlands.
The study was started in 1959 in Finland and in
1960 in Italy and the Netherlands. Baseline dietary
information used in this study was gathered in 1969 in
the Finnish cohorts and in 1970 in the Dutch cohort
and one Italian cohort (Crevalcore). As the 1970 data
from Montegiorgio were available only on a non›
random subset of men, the dietary data gathered in
1965 from the men who were still alive in 1970 were
used as an approximation for dietary intake in 1970.
This is justifiable because dietary intake in Finland,
Italy, and the Netherlands was relatively stable within
the cohorts during the first 10 years of the seven
countries study.12
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Information on diet around 1970 was available for
612 men in eastern Finland, 694 men in western
Finland, 615 men in Zutphen, and 592 men in Creval›
core. We had dietary information in 1965 for 662 men
in Montegiorgio. The analyses in this study are based
on subjects for whom complete information on diet
and confounding variables was available at baseline
(1969›70): 606 men from eastern Finland (89%), 683
men in western Finland (91%), 608 men in Zutphen
(79%), 591 men in Crevalcore (69%), and 557 men in
Montegiorgio (85%)
Collection of information
Food intake around 1970 was estimated with the cross
check dietary history method, adapted to the local
situation and carried out by experienced dietitians and
nutritionists. This method provides information about
the usual food consumption pattern in the 6›12
months preceding the interview.14›18 The usual food
consumption pattern of the subject during weekdays
and weekends was assessed by recording foods eaten at
breakfast, lunch, and dinner, and between meals. This
information was checked by registering from a
comprehensive food list the frequency and amount of
foods consumed and, in the case of discrepancies, dis›
cussing the recorded food consumption pattern with
the participant. This method has satisfactory repro›
ducibility.19 20 In Finland the interviews were carried out
in autumn and in the Netherlands and Italy in spring.
Nutrient intakes were assessed by using computerised
versions of food tables for each country.16 18 21
Information about cigarette smoking was collected
by a standardised questionnaire. Subjects were
classified as men who had never smoked, men who had
stopped smoking, and current smokers. Men who
never drank alcohol were classified as abstainers. On
the basis of mortality in Italian men, moderate drinkers
were categorised as men who consumed up to six
glasses of alcohol a day. Those who drank more than
six glasses a day were categorised as heavy drinkers.22
The men were followed for mortality for 20 years.
None of the men was lost to follow up. The underlying
cause of death was coded in a standardised way by one
reviewer (AM), using the eighth revision of the
international classification of diseases (ICD›8). The
cause of death was based on information from the
official death certificate, in combination with infor›
mation from medical and hospital records. In Finland,
after the fifth year of follow up only death certificates
were available for assigning the cause of death. The
coder of the causes of death was blind to the risk factor
status of the subject. In the case of multiple causes of
death, priority was given to accidents, followed by
cancer in advanced stages, coronary heart disease, and
stroke. For the present analyses cardiovascular disease
was defined as ICD›8 codes 390›450 and A795 (code
A795 was a special choice of the study group, identify›
ing sudden death of probable coronary origin,
occurring within two hours of the onset of symptoms).
Cancer was defined as ICD›8 codes 140›239. Other
causes included all other deaths not covered in these
rubrics.
Dietary measures
The healthy diet indicator was calculated by using the
dietary guidelines for the prevention of chronic
diseases, defined by the WHO.11 A dichotomous
variable was generated for each food group or nutrient
that was included in these guidelines (table 1). If a per›
son’s intake was within the recommended range this
variable was coded as 1; otherwise it was coded as 0.
The healthy diet indicator was the sum of all these
dichotomous variables.
To avoid overlap, total fat and total carbohydrates
were omitted in the calculation of the healthy diet indi›
cator. Salt was not included because only information
about the sodium content in foods was available and it
was not known how much salt was added during
preparation of meals and at the table. We used the vari›
able “monosaccharides and disaccharides” instead of
free sugars because the free sugars variable was not
comparable between the countries. The use of
monosaccharides and disaccharides has overestimated
the actual intake of free sugars, especially in Finland,
where the intake of milk products and therefore of lac›
tose is high. Alcohol consumption in Italy was higher
than in the two other countries, so for all three
countries, before the intake of macronutrients was
entered in the healthy diet indicator it was calculated as
a percentage of energy intake without the energy pro›
vided by alcohol.
Both in the pooled populations and in each
country separately, participants were divided into
thirds (low, medium, and high) according to their
healthy diet indicator. In Finland and the Netherlands,
and also in the pooled populations, cut off values were
< 2, 2, and > 2. In Italy the cut off values were < 3, 3›4,
and > 4.
Statistics
Differences in baseline characteristics between cohorts
were tested with analysis of variance, using ScheffØ’s
test for multiple comparisons. Frequencies of categori›
cal variables in the different cohorts were compared by
the ÷2 test. Cox’s proportional hazards survival analysis
was used to investigate the relation between healthy
diet indicator groups and mortality in the total study
population after a model including the interaction
between healthy diet indicator and country had been
tested. Adjustments were made for age at baseline,
cigarette smoking, and alcohol consumption. All
confounders except age at baseline were entered in the
model as dummy variables. Analyses were repeated for
each country separately. All P values were based on two
sided tests, and a P value of 0.05 was considered to be
Table 1 Criteria used for healthy diet indicator (dichotomous
values), based on the dietary guidelines for the prevention of
chronic diseases.11 Values are percentage of energy intake unless
indicated otherwise
Nutrient or food group (daily intake)
Dichotomous value
1 0
Saturated fatty acids 0›10 >10
Polyunsaturated fatty acids 3›7 <3 or >7
Protein 10›15 <10 or >15
Complex carbohydrates 50›70 <50 or >70
Dietary fibre (g) 27›40 <27 or >40
Fruits and vegetables (g) >400 <400
Pulses, nuts, seeds (g) >30 <30
Monosaccharides and disaccharides 0›10 >10
Cholesterol (mg) 0›300 >300
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significant. The sas statistical analysis computer
package (version 6.10) was used.
Results
Out of the total study population of 3045 men, 1796
men (59%) died during 20 years of follow up (table 2).
Mortality was highest in eastern Finland and lowest in
Montegiorgio. Mean age at baseline varied between 58
and 60 years and was significantly lower in eastern
Finland than in western Finland, Zutphen, and Creval›
core. The percentage of smokers varied from 42% to
57%, and alcohol intake varied greatly among the
cohorts.
Dietary intake around 1970 varied greatly between
the cohorts (table 3). Median energy intake ranged
from 11 MJ to 15 MJ, and nutrient intake varied
greatly: for example, median saturated fatty acid
intake was 22% in Finland and 9% in Montegiorgio,
Italy. The minimum healthy diet indicator was 0; the
maximum healthy diet indicator varied from 5 in Fin›
land to 8 in Italy. The healthy diet indicator was
positively associated with alcohol intake (r = 0.42,
P = 0.0001). A significant but small inverse association
(r = − 0.05, P = 0.005) with cigarette smoking was
found.
The healthy diet indicator was inversely related to
all cause mortality in the pooled population analyses
(table 4). The crude analysis showed a 15% lower risk of
deaths from all causes in the group with the highest
healthy diet indicator. After adjustment for age,
cigarette smoking, and alcohol consumption the all
cause mortality risk was 13% lower. In an additional
analysis the interaction between healthy diet indicator
and country was not significant (P > 0.20); we therefore
considered it appropriate to do a pooled analysis. In
separate analyses, the healthy diet indicator and all
cause mortality were inversely associated in each
country; the association was similar to that in the
pooled populations but was not significant.
Although the relative risks for all cause mortality
were within the same order of magnitude for the three
countries, the absolute mortality was highest in Finland
and lowest in Italy (fig 1). Men with the healthiest diet
in Finland had higher mortality than the men with an
unhealthy diet in Italy, but absolute risks in the Nether›
lands and Italy were similar.
Overall, after adjustment for confounders, the
group with the highest healthy diet indicator had an
Table 2 Characteristics of cohorts in 1969 (Finland) and 1970 (Italy and Netherlands) followed for 20 years
Finland
Netherlands (n=608)
Italy
Eastern (n=606) Western (n=683) Crevalcore (n=591) Montegiorgio (n=557)
No who died (from all causes) 395 412 346 346 297
Person years 8408 9942 9239 8588 8527
Mortality (No died/1000 person years) 47 41 37 40 35
Mean (SD) age in 1970 58.3 (5.4) 59.6 (5.5)* 59.5 (5.3)* 59.5 (5.0)* 59.1 (4.8)
No (%) smoking in 1970†:
Never smokers 78 (12.9) 171 (25.0) 46 (7.6) 160 (27.1) 177 (31.8)
Former smokers 180 (29.7) 223 (32.7) 241 (39.6) 127 (21.5) 98 (17.6)
Present smokers 348 (57.4) 289 (42.3) 321 (52.8) 304 (51.4) 282 (50.6)
No (%) consuming alcohol†:
Abstainers 226 (37.3) 248 (36.3) 172 (28.3) 27 (4.6) 8 (1.4)
Moderate (<60 g/day) 372 (61.4) 422 (61.8) 432 (71.1) 266 (45.0) 2317 (39.0)
Heavy (>60 g/day) 8 (1.3) 13 (1.9) 4 (0.6) 298 (50.4) 332 (59.6)
*P<0.05 (ScheffØ test, multiple comparisons) for difference from eastern Finland.
†P<0.05 (÷2 test) for difference between cohorts.
Table 3 Median (range) of daily intake in 1970 of dietary components on which healthy diet indicator was based. Values are
percentage of energy intake unless indicated otherwise
Finland
Netherlands
Italy
East West Crevalcore Montegiorgio
Energy (MJ) 14.8 (5.2›33.6) 15.4 (5.1›45.7) 10.7 (4.1›20.8) 12.2 (3.3›26.0) 11.7 (4.1›28.0)
Saturated fatty acids 21.7 (9.7›40.6) 21.6 (8.0›36.7) 17.5 (5.8›28.1) 14.1 (2.5›28.6) 9.2 (3.1›23.1)
Polyunsaturated fatty acids 2.8 (1.8›7.2) 2.9 (1.4›5.4) 6.7 (1.3›18.6) 4.6 (1.3›13.6) 3.5 (1.6›20.4)
Protein 12.7 (7.2›20.2) 12.7 (5.4›19.4) 12.7 (6.3›23.1) 14.9 (7.9›24.0) 11.6 (7.1›21.4)
Complex carbohydrates 23.5 (6.5›42.9) 25.0 (8.9›41.5) 22.4 (8.7›35.8) 36.3 (9.3›65.6) 49.3 (20.3›69.6)
Dietary fibre (g) 37.9 (6.2›108.9) 35.1 (6.9›111.2) 23.7 (6.4›51.1) 28.9 (4.1›87.7) 35.9 (8.0›98.3)
Fruits and vegetables (g) 200.1 (4.7›1479.6) 209.8 (0.9›3067.9) 333.5 (0›1433) 250.0 (0›1717) 137.0 (6.0›844.0)
Pulses, nuts, seeds (g) 4.1 (0›53.8) 6.0 (0›59.3) 3 (0›71) 0 (0›50) 2.0 (0›117.0)
Monosaccharides and disaccharides 25.2 (10.6›52.0) 23.5 (12.2›64.0) 21.6 (6.2›45.4) 11.4 (1.5›34.3) 4.8 (1.5›24.9)
Cholesterol (mg) 627 (136›2209) 649 (215›1907) 374 (76›1305) 349 (36›1043) 202 (22›909)
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18% lower risk of death from cardiovascular disease
than the group with the lowest healthy diet indicator
(P for trend < 0.05). Risk of death from cancer was
15% lower in the highest group than in the lowest
group (P for trend = 0.13).
Discussion
This study shows that 20 year mortality is lowest in
men with the healthiest diet according to WHO
recommendations. After adjustment for age, cigarette
smoking, and alcohol consumption, the group with the
highest healthy diet indicator had a 13% lower risk of
death than the group with the lowest. The healthy diet
indicator had an even stronger inverse association with
mortality from cardiovascular diseases.
Dietary patterns
Several other studies have examined dietary patterns
or a combination of nutrients instead of single
nutrients or dietary components, but these were all
done within single countries.7›10 23 24 Trichopoulou and
coworkers recently used an approach similar to ours.
They assessed the influence of a specific dietary pattern
on overall survival among 182 elderly residents of
three rural Greek villages. A diet score was calculated
on the basis of eight component characteristics of the
traditional Mediterranean region; an increase of one
unit was associated with a 17% reduction in overall
mortality.8 Nube and coworkers investigated the effect
of a dietary score on longevity among 2820 middle
aged Dutch civil servants. Using the recall of the
frequency of intake of particular foods instead of an
extensive dietary history, they found a significant linear
trend for 25 year survival from highest (healthiest) to
lowest scores.7 Our results confirm these national
results.
Since dietary patterns are highly determined by
cultural influences (for example, the Mediterranean
dietary pattern25›27 ), we did not adjust for country in the
pooled population analyses. Country has a strong
cultural component which is responsible for (part of)
the variation in dietary patterns. Adjustment for this
variable would result in an overcorrection and hence
an underestimation of the true association between the
quality of the diet and mortality. When the countries
were analysed separately, the associations between the
healthy diet indicator and all cause mortality were
essentially the same, although they no longer reached
significance. This was due to a low statistical power
resulting from the smaller numbers of subjects within a
country.
In our analyses we assumed that the diet around
1970 is indicative of diet between 1970 and 1990. The
general dietary patterns in the different cultures can
still be recognised after 20 years, but the differences
between them have become smaller.13 This may have
resulted in attenuation of the association.
Healthy diet indicator
To assess whether one of the components of the
healthy diet indicator could be responsible for the
observed association with mortality, we analysed the
same models for each of the components of the
healthy diet indicator separately. For most of the com›
ponents the association was not significant (data not
shown), and different components were responsible for
the association in different countries. Trichopoulou
and coworkers, too, found significant results for only
one of the individual components.8 We therefore con›
cluded that the dietary pattern as a whole, as reflected
in the healthy diet indicator, was responsible for the
observed association.
Though some of the criteria of the healthy diet
indicator overlap and some of the variables may be U
shaped, we found a significant inverse association with
20 year mortality. The healthy diet indicator will be
refined in future studies.
Alcohol intake and energy intake
Alcohol intake varied greatly among the cohorts. In
Italy mean alcohol intake was on average 10 times
higher than in Finland. Giving macronutrient intakes
within total energy intake would be misleading, since
the high alcohol intake in the Italian cohorts would
dilute macronutrient intake in comparison to that in
Finland and the Netherlands. To separate the effect of
alcohol from that of the healthy diet indicator, in each
of the countries we calculated macronutrient intake
relative to energy intake excluding energy from
alcohol. We regarded alcohol intake as a possible con›
founder in the association of the healthy diet indicator
with mortality. The high cut off for moderate alcohol
consumption was chosen for practical reasons.
Although these categories were rather crude, residual
confounding would not have resulted in large artefacts
since inverse associations between alcohol intake and
Table 4 Risk of death from all causes in 3045 men aged 50›70 years at baseline
Relative risk (95% CI) P value
for trendLow* Medium* High*
Pooled populations
No of subjects 785 969 1291
Mean healthy diet indicator 0.9 2.0 4.0
Mortality†: 42 42 37
Crude 1.00 1.00 (0.88 to 1.13) 0.85 (0.76 to 0.96) 0.004
Adjusted for age 1.00 0.95 (0.84 to 1.07) 0.82 (0.73 to 0.92) 0.0006
Adjusted for confounders‡ 1.00 0.99 (0.87 to 1.11) 0.87 (0.77 to 0.98) 0.03
Finland
No of subjects 529 552 208
Mean healthy diet indicator 0.9 2.0 3.1
Mortality†: 46 44 41
Crude 1.00 0.96 (0.83 to 1.11) 0.89 (0.72 to 1.09) 0.25
Adjusted for age 1.00 0.93 (0.80 to 1.08) 0.86 (0.70 to 1.06) 0.14
Adjusted for confounders‡ 1.00 0.97 (0.83 to 1.12) 0.90 (0.73 to 1.10) 0.31
Netherlands
No of subjects 139 214 255
Mean healthy diet indicator 0.9 2.0 3.4
Mortality†: 37 40 35
Crude 1.00 0.95 (0.74 to 1.20) 0.79 (0.57 to 1.11) 0.20
Adjusted for age 1.00 0.93 (0.73 to 1.19) 0.73 (0.52 to 1.02) 0.08
Adjusted for confounders‡ 1.00 0.91 (0.72 to 1.16) 0.75 (0.53 to 1.05) 0.09
Italy
No of subjects 320 459 369
Mean healthy diet indicator 1.6 3.4 5.5
Mortality†: 38 39 33
Crude 1.00 1.01 (0.83 to 1.22) 0.85 (0.69 to 1.04) 0.11
Adjusted for age 1.00 1.04 (0.86 to 1.26) 0.86 (0.70 to 1.06) 0.13
Adjusted for confounders‡ 1.00 1.04 (0.86 to 1.26) 0.89 (0.72 to 1.09) 0.23
*In the pooled population, in Finland, and in the Netherlands, cut off values for the thirds were:
low <2, medium 2, high >2; in Italy the cut off values were: low <3, medium 3 or 4, high >4.
†No of deaths per 1000 person years.
‡Adjusted for age, cigarette smoking, and alcohol consumption.
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mortality have been observed for up to six glasses per
day.22
To adjust for physical activity in the survival analy›
ses, we calculated energy intake per kilogram of body
weight as an approximation.28 The results were
essentially the same as without the adjustment (data
not shown). Since no other reliable measure of physical
activity was available we could not adjust for it in the
present study.
Mortality
Besides all cause mortality, we were also able to investi›
gate mortality from cardiovascular diseases and cancer,
the most important causes of premature death in
developed industrialised countries.11 There is abundant
evidence that diet affects these diseases, and this was
recognised in the WHO recommendations for the pre›
vention of chronic diseases. Our results show that these
recommendations may be effective. The healthy diet
indicator, which was based on the WHO recommenda›
tions, was associated not only with reduced all cause
mortality but with an even stronger reduced mortality
from cardiovascular diseases.
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Key messages
x Studying dietary patterns instead of single
nutrients in relation to mortality takes into
account the intercorrelation of nutrients in the
diet
x A healthy diet, as measured by an indicator
based on WHO recommendations, is
associated with a reduction of 13% after 20
years in all cause mortality for men aged
50›70
x The dietary pattern as a whole is more
important than specific dietary components
with respect to survival among older
people
x The WHO dietary recommendations for the
prevention of chronic diseases seem to be
effective
x The healthy diet indicator is useful for
evaluating the relation of dietary patterns and
mortality in a cross cultural setting
Endpiece
A very short report admired by
Dr Johnson
Johnson said he could repeat a complete chapter
of The Natural History of Iceland, from the Danish of
Horrebow, the whole of which was exactly thus:–
“CHAP. LXXII. Concerning snakes. There are no
snakes to be met with throughout the whole
island.”
James Boswell, The Life of Samuel Johnson
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Substance use in remand prisoners: a consecutive case
study
Debbie Mason, Luke Birmingham, Don Grubin
Abstract
Objectives: To determine the prevalence of drug and
alcohol use among newly remanded prisoners, assess
the effectiveness of prison reception screening, and
examine the clinical management of substance
misusers among remand prisoners.
Design: A consecutive case study of remand prisoners
screened at reception for substance misuse and
treatment needs and comparison of findings with
those of prison reception screening and treatment
provision.
Setting: A large adult male remand prison (Durham).
Subjects: 548 men aged 21 and over awaiting trial.
Main outcome measures: Prevalence of substance
misuse; treatment needs of substance misusers;
effectiveness of prison reception screening for
substance misuse; provision of detoxification
programmes.
Results: Before remand 312 (57%) men were using
illicit drugs and 181 (33%) met DSM›IV drug misuse
or dependence criteria; 177 (32%) men met misuse or
dependence criteria for alcohol. 391 (71%) men were
judged to require help directed at their drug or
alcohol use and 197 (36%) were judged to require a
detoxification programme. The prison reception
screen identified recent illicit drug use in 131 (24%) of
536 men and problem drinking in 103 (19%). Drug
use was more likely to be identified by prison
screening if an inmate was using multiple substances,
using opiates, or had a diagnosis of abuse or
dependence. 47 (9%) of 536 inmates were prescribed
treatment to ease the symptoms of substance
withdrawal.
Conclusions: The prevalence of substance misuse in
newly remanded prisoners is high. Prison reception
health screening consistently underestimates drug
and alcohol use. In many cases in which substance use
is identified the quantities and numbers of different
substances being used are underestimated. Initial
management of inmates identified by prison
screening as having problems with dependence
producing substances is poor. Few receive a
detoxification programme, so that many are left with
the option of continuing to use drugs in prison or
facing untreated withdrawal.
Introduction
There has been a dramatic increase in the use of illicit
drugs in England and Wales in recent years. This is
reflected in the increase in numbers of notifiable drug
addicts from around 17 000 in 1990›1 to around
33 000 in 1995›6. An even steeper rise has been noted
in prisoners, who accounted for 12% of notifications in
1990 and 23% in 1995.1 In addition to the general
social problems and adverse effects on health
associated with illicit drug use, there are particular
problems secondary to drug use in prison, such as the
fostering of gangs, debt to other prisoners, and
violence.
We recently reported that 26% of men newly
remanded to a large prison in north east England had
some form of mental disorder (excluding drug and
alcohol misuse diagnoses) at the point of reception.2 By
using data on substance use from the same subjects
this paper reports on the prevalence of drug and
alcohol use, the extent to which prison reception
screening detects this, and the initial management of
subjects whose substance misuse is identified.
Subjects and methods
The study was conducted at Durham prison, a typical
male remand and short sentence prison. All new
prisoners are screened at reception by a healthcare
officer for physical and mental health problems as well
as substance use. A standard prison questionnaire
(F2169) is used which contains several specific
questions about recent drug and alcohol use. This pro›
vides useful information for the prison doctor, who
assesses each inmate the next working day and decides
about detoxification regimens and any other treatment
needs. All unconvicted men remanded into custody
over seven months from 1 October 1995 to 30 April
1996 were eligible for the study. The research was
explained to each man and assurances given that any
information he offered was confidential and would not
be passed on to prison staff. Each man gave written
consent. Subjects were interviewed by one of two
researchers trained in psychiatry.
Screening
A semistructured interview designed specifically for
the study was used. A comprehensive drug and alcohol
history was taken, levels of use recorded, and DSM›IV
(Diagnostic and Statistical Manual of Mental Disorders,
fourth edition) diagnoses of abuse and dependence
made when appropriate. The CAGE questionnaire3
was incorporated to help detect problem drinking and
the severity of dependence scale4 was used to quantify
severity of drug dependence.
Virtually all interviews were conducted on the
working day after reception into prison, shortly after
the medical officer had seen the inmate. Interviews
lasted between 20 minutes and one hour depending
on the complexity of an inmate’s presentation. On the
basis of our findings a decision was made about
suitability for a detoxification programme. After each
inmate had been interviewed his medical record was
examined. The findings of the healthcare officer’s
screen and the prison doctor’s assessment were
recorded and any treatment prescribed was noted.
A pilot study was undertaken. During the pilot
study and throughout the main study, interrater
reliability was monitored. A total of 116 prisoners were
interviewed by one researcher in the presence of the
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other. Both researchers recorded lifetime diagnoses
independently. From this information the agreement
between raters was measured by means of a ê
coefficient.5 Agreement in this setting is likely to be
higher than with separate interviews; given the practi›
calities of research in prison, separate interviews were
not feasible.
Results
During the study 606 unconvicted men were newly
remanded to Durham prison. Of those available for
interview, 548 were comprehensively screened for sub›
stance use. In the 116 interviews that were jointly rated
to asses interrater reliability, 184 separate diagnoses of
substance misuse were recorded by either one or both
raters. There was diagnostic agreement in 175 cases
(ê = 0.930).
Prevalence and patterns of substance use
A total of 382 men (70%; 95% confidence interval 66%
to 74%) gave a history of illicit drug use at some point
in their lives. Of these men, 312 (57%; 53% to 61%) said
they had used illicit drugs in the past year and 181
(33%; 29% to 37%) currently met abuse or dependence
criteria for one or more drugs. Table 1 gives the
numbers of men currently using each class of drug
according to level of use. Many inmates using drugs
complained of withdrawal symptoms, but only 12 diag›
noses of drug withdrawal syndrome were made.
Intravenous drug use was reported by 101 men
(26%; 22% to 30%), 29 of whom said they had shared
needles. Table 2 shows the extent of multiple drug use.
Of the 181 subjects with drug abuse or dependence
diagnoses, 60 had two such diagnoses and 20 had three
or more.
Treatment needs and expectations of substance
users
Of 391 men (71%; 67% to 76%) who admitted using
illicit drugs regularly or abuse of or dependence on
alcohol, or both, and who were judged to require treat›
ment directed at their substance use, 244 (62%; 58% to
66%) said they wanted help. A total of 197 (36%; 32%
to 40%) of the study population who were physio›
logically dependent on benzodiazepines, alcohol,
opiates, or a combination of these substances at the
time of reception into prison were judged to be poten›
tial candidates for a detoxification programme. Of
these, 64 requested treatment including detoxification,
22 wanted methadone maintenance, 45 wanted other
treatments such as group work, and 66 did not want
help.
Alcohol use
Table 3 shows the levels of reported alcohol use in the
previous year. Four diagnoses of acute alcohol
withdrawal syndrome were made.
Detection of substance use by reception screening
The inmate medical records of 536 of the 548 subjects
were inspected. In general the healthcare officers’
screens were more comprehensive than the doctors’
assessments. In particular, they contained information
about which substances were being used whereas the
doctors’ assessments usually just recorded “drugs”
when their use was detected and “alcohol abuse” when
alcohol consumption was thought to be excessive. To
some extent prison screens are designed to be comple›
mentary and doctors may have thought it unnecessary
to duplicate information recorded by the healthcare
worker. However, in cases in which the healthcare
worker had not detected substance use but this had
been identified subsequently by the doctor, infor›
mation was still minimal. In most cases when it would
have been appropriate to do so, neither screen sought
further information on quantities of substances used
or problems associated with substance use.
Drugs
The healthcare officers’ questionnaire identified 131 of
536 subjects (24%; 20% to 28%) using illicit drugs
recently. Table 4 shows the detection rates for each of
the four drugs that we identified as being used most
commonly. The healthcare officers’ screen detected 56
of the 81 subjects we had identified as currently
dependent on opiates (difference = 0.046; 0.028 to
0.063), 22 of the 70 subjects we identified as currently
dependent on illicit benzodiazepines (differ›
ence = 0.088; 0.076 to 0.100), and 15 of the 43 we iden›
tified as currently dependent on amphetamines
(difference = 0.051; 0.032 to 0.069).
Subsequent interviews with the prison medical
officer identified a further 42 subjects as “using drugs”
(without identifying the class of drug ), increasing the
number detected to 172 (32%; 28% to 36%). Six
subjects who when asked by us denied ever using illicit
drugs were identified by prison screening as using
cannabis.
Table 1 Numbers of subjects currently using each class of illicit drug at recreational
(non›abusive or non›dependent use), DSM›IV abuse and DSM›IV dependence levels
(n=312 subjects*)
Drug Recreational use Abuse Dependence Total
Amphetamine 67 25 44 136
Benzodiazepines 32 12 75 119
Cannabis 244 13 1 258
Cocaine 35 8 4 47
Hallucinogens 32 4 0 36
Opiates 13 3 84 100
Solvents 4 0 5 9
Other substances 2 5 1 8
*Many subjects were using more than one illicit substance.
Table 2 Numbers of illicit drugs used by 312 subjects
No of drugs used currently No (%) of subjects
1 108 (34.6)
2 96 (30.7)
3 55 (17.6)
4 27 (8.7)
5 17 (5.4)
6 8 (2.6)
7 1 (0.3)
Table 3 Current levels of alcohol use in 548 subjects
Level of use No (%) of subjects
None 122 (22)
< 21 U/week 193 (35)
> 21 U/week (with no DSM›IV alcohol diagnosis) 56 (10)
DSM›IV abuse 61 (11)
DSM›IV dependence 116 (21)
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Drug users were increasingly likely to be detected
by the prison reception screen as the number of drugs
they were using increased (P < 0.0001, ÷2 = 60.14;
df = 6) and if they had one or more current drug abuse
or dependency diagnoses (P < 0.0001, ÷2 = 56.90;
df = 1).
Alcohol
Problem drinking was identified by one or both prison
screens in 88 of the 172 subjects identified by us as
having a current alcohol abuse or dependency diag›
nosis. A further 15 men were said to have alcohol
problems when no alcohol diagnosis was made by us
(difference = 0.133; 0.099 to 0.168).
Provision of detoxification programmes
Of 197 subjects potentially requiring a detoxification
regimen, 113 needed a reducing course of benzo›
diazepines to ease withdrawal from benzodiazepines or
alcohol or both. Only six men (5%) received this,
though a further five men were prescribed benzo›
diazepines for other reasons. Forty two subjects were
judged by us to require methadone detoxification, of
whom 15 (36%) received it; three men were given
benzodiazepines instead. A further 42 subjects
potentially required detoxification with both benzo›
diazepines and methadone, of whom 10 received this,
nine were given methadone alone, and four were given
benzodiazepines alone.
Discussion
Before their reception into Durham prison over 70%
of unconvicted remand prisoners reported the use of
illicit drugs, regular consumption of excessive amounts
of alcohol, or both. Amounts of drugs and alcohol con›
sumed were often substantial, reflected by 56% of the
population having one or more current diagnoses of
substance abuse or dependency. Multiple substance
use was also common.
Our results show that whereas over one third of all
newly remanded prisoners provisionally needed to be
considered for detoxification, only about one in four
actually received treatment to help manage withdrawal
from drugs and alcohol. Clinical assessment of
substance use at reception relies to a large extent on
self reporting. We found that when questioned by
prison staff many inmates played down the extent of
their substance use, disclosing only what they thought
was necessary, as they were not confident of receiving
treatment but risked being labelled as drug users.
When interviewed by researchers, who were not
perceived to be part of the system, inmates seemed
more willing to disclose substance misuse. The fact
remains, however, that substantial numbers of drug
users were missed by prison reception screening.
Though considerable emphasis has so far been
placed on the role of the inmate, this is not the only
factor that determines the effectiveness of screening
for substance use. We found that information recorded
by prison staff at the time of reception was often
inadequate or ambiguous. Such standards have led to
criticism of prison medical staff in the past.6 7 Concern
has also been expressed about treatment programmes
for drug misusers in prisons based on Home Office
guidelines, which are said to breach normal standards
of professional ethical care.8
The prison service has other means than clinical
assessment of identifying drug use which do not rely so
heavily on a prisoner’s cooperation. Compulsory urine
testing of prisoners for drugs, with penalties for
positive results or refusal, was piloted in early 1995.
Despite a lack of evidence for its effectiveness in reduc›
ing drug use, testing was extended to all prisons in
England and Wales by March 1996. The cost of this
programme is estimated at around half the total
healthcare expenditure for a prison of 500.9 This is
primarily a deterrent measure, however, as tests give
little information about substance related problems or
health needs and are not a substitute for thorough
clinical assessment. We believe that if drug use in
prison is to be tackled effectively greater emphasis
needs to be placed on more rigorous clinical screening
and provision of drug treatment programmes com›
parable to those in the community.
There are no other published studies of substance
misuse at the time of reception into prison in the
Table 4 Numbers identified by hospital officers’ screening according to level of use of
four most frequently encountered illicit drugs
Drug
Level of use according to
research screening
Use identified by hospital officer
No Yes
Cannabis Not used 118 6
Recreational 191 45
Abuse or dependence 10 4
Amphetamines Not used 234 4*
Recreational 58 7
Abuse or dependence 45 23
Benzodiazepines Not used 256 2*
Recreational 33 3
Abuse or dependence 61 22
Opiates Not used 274 4*
Recreational 11 0
Abuse or dependence 25 57
*All subjects identified by study as currently using illicit drugs other than cannabis.
Key messages
x In screening for substance use in remand
prisoners a positive finding must be considered
the norm rather than the exception
x Present prison reception procedures fail to
identify the extent to which substances are used
and misused by people newly remanded to
prison
x Provision of detoxification programmes for
prisoners identified by reception screening as
having serious drug and alcohol related
problems is inadequate
x Prisoners who need help but think that asking
for this is more likely to result in punishment
than treatment are not likely be truthful about
their substance use
x More consideration needs to be given to
reducing substance misuse in prisons by
improving assessment at reception and
providing better treatment for misusers rather
than using random urine screening to detect
and punish offenders
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United Kingdom, but there is no reason to suspect that
the scale of the problem differs in other remand
prisons. A recent national study of mental disorder in
remand prisoners by Brooke et al reported harmful or
dependent misuse of alcohol or other drugs in 38% of
subjects10 (compared with a similar finding in 56% of
our population). There are, however, important differ›
ences between their study and our own. Many of the
inmates screened by Brooke et al had already spent a
considerable period on remand before being inter›
viewed (median time 64 days), and therefore the results
of their study cannot be interpreted as accurately
reflecting the scale of substance misuse at the point of
reception. In addition, Brooke et al reported a much
higher refusal rate (18% compared with 3% in this
study), which may have biased their results.
Without adequate detoxification programmes
many inmates will continue to use drugs in prison. In
some cases this will be accompanied by the risk of
needle sharing. Others who attempt to stop or who do
not establish a supply quickly enough are exposed to
the effects of acute withdrawal. Ultimately the picture
that emerges is one of a self perpetuating and rapidly
growing problem of substance use in prisons, which,
because most prisoners are released after compara›
tively short periods (the mean length of remand was
under two months in our sample), will inevitably spill
over into the community.
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Harm reduction measures and injecting inside prison
versus mandatory drugs testing: results of a cross sectional
anonymous questionnaire survey
A Graham Bird, Sheila M Gore, Sharon J Hutchinson, Stephanie C Lewis, Sheila Cameron,
Sheila Burns on behalf of the European Commission Network on HIV infection and
hepatitis in prison
Abstract
Objectives: (a) To determine both the frequency of
injecting inside prison and use of sterilising tablets to
clean needles in the previous four weeks; (b) to assess
the efficiency of random mandatory drugs testing at
detecting prisoners who inject heroin inside prison;
(c) to determine the percentage of prisoners who had
been offered vaccination against hepatitis B.
Design: Cross sectional willing anonymous salivary
HIV surveillance linked to a self completion risk
factor questionnaire.
Setting: Lowmoss prison, Glasgow, and Aberdeen
prison on 11 and 30 October 1996.
Subjects: 293 (94%) of all 312 inmates at Lowmoss
and 146 (93%) of all 157 at Aberdeen, resulting in 286
and 143 valid questionnaires.
Main outcome measures: Frequency of injecting
inside prison in the previous four weeks by injector
inmates who had been in prison for at least four
weeks.
Results: 116 (41%) Lowmoss and 53 (37%) Aberdeen
prisoners had a history of injecting drug use but only
4% of inmates (17/395; 95% confidence interval 2%
to 6%) had ever been offered vaccination against
hepatitis B. 42 Lowmoss prisoners (estimated 207
injections and 258 uses of sterilising tablets) and 31
Aberdeen prisoners (229 injections, 221 uses) had
injected inside prison in the previous four weeks. The
prisons together held 112 injector inmates who had
been in prison for more than four weeks, of whom 57
(51%; 42% to 60%) had injected in prison in the past
four weeks; their estimated mean number of
injections was 6.0 (SD 5.7). Prisoners injecting heroin
six times in four weeks will test positive in random
mandatory drugs testing on at most 18 days out of 28.
Conclusions: Sterilising tablets and hepatitis B
vaccination should be offered to all prisoners.
Random mandatory drugs testing seriously
underestimates injector inmates’ harm reduction
needs.
Introduction
Willing anonymous salivary HIV (WASH) surveillance
in Scottish prisons provided consistent estimates in
1991›5 of the prevalence of risk behaviours inside and
outside prisons, of their geographic and sentencing
correlates, and of the prevalence of HIV among
injector inmates.1›4 Two studies in 1996 were important
for different reasons5: the study in Lowmoss prison,
Glasgow, monitored changes since willing anonymous
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salivary HIV surveillance in 1994 at Barlinnie prison,
also in Glasgow; the study in Aberdeen prison gave the
first insight to injector and HIV prevalence in north
east Scotland at a time of concern about the availability
of cheap heroin.6
Questions were added in 1996 to evaluate
prisoners’ access to harm reduction measures, includ›
ing hepatitis B vaccination. Sterilising tablets have been
available to all Scottish prisoners since December 1993
for purposes including the cleaning of needles and
works. But are they being used for the intended harm
reduction purpose? Random mandatory drugs testing
has been challenged as “a means of gathering
information.”7 8 We used volunteered information on
the frequency of injecting inside prison in the previous
four weeks to estimate the likely efficiency of random
mandatory drugs testing at detecting inmates who
inject class A drugs such as heroin inside prison. So far
as we know this is the first such study.
Methods
Willing anonymous salivary HIV surveillance was con›
ducted with ethical approval and as described1›3 9 by
external teams of volunteers at Lowmoss prison on 11
October and at Aberdeen prison on 30 October 1996.
Saliva samples were tested for HIV antibodies at the
regional virus laboratories in Glasgow and Edinburgh
respectively. On the surveillance days AGB briefed
prisoners about why the survey was being performed,
Table 1 Composition of study groups in HM prisons Lowmoss
and Aberdeen
Lowmoss Aberdeen
Total No of prisoners 312 157
Total No of respondents 293 146
Response rate (%) (94) (93)
No (%) excluded for failing logical checks 7 (2) 3 (2)
No completing valid questionnaire 286 143
Table 2 Results of questionnaire survey at Lowmoss and Aberdeen. Figures are numbers (percentages) of prisoners
Lowmoss Aberdeen
All participants
(n=286)
Injector inmates
(n=116)
All participants
(n=143)
Injector inmates
(n=53)
Q9 In which year did you first inject drugs (excluding insulin)?
No of non›respondents 4 0 1 0
Never injected 166 (59) 0 89 (63) 0
1982 or earlier 20 (7) 20 (17) 6 (4) 6 (11)
1983›5 27 (10) 27 (23) 2 (1) 2 (4)
1986›8 17 (6) 17 (15) 4 (3) 4 (8)
1989›91 17 (6) 17 (15) 9 (6) 9 (17)
1992›4 19 (7) 19 (16) 13 (9) 13 (25)
1995 or later 16 (6) 16 (14) 19 (13) 19 (36)
Q10 When did you last inject drugs before coming into prison this time (including remand prison)?
No of non›respondents 7 3 2 1
Never injected 166 (59) 0 92 (65) 3 (6)
On day came into prison 21 (8) 21 (19) 15 (11) 15 (29)
On day before coming into prison 40 (14) 40 (35) 12 (9) 12 (23)
In week before coming into prison 12 (4) 12 (11) 6 (4) 6 (12)
Between one and four weeks before coming into prison 7 (3) 7 (6) 6 (4) 6 (12)
More than four weeks before coming into prison 33 (12) 33 (29) 10 (7) 10 (19)
Q11 Have you ever injected while inside?
No of non›respondents 10 0 1 0
Yes 66 (24) 66 (57) 39 (27) 39 (74)
No 210 (76) 50 (43) 103 (73) 14 (26)
Q12 Did you start injecting while inside?
No of non›respondents 19 1 6 1
Yes 5 (2) 5 (4) 10 (7) 10 (19)
No 262 (98) 110 (96) 127 (93) 42 (81)
Q14 How many times have you injected drugs in prison in last four weeks?
No of non›respondents 12 2 1 0
Never 232 (85) 72 (63) 111 (78) 22 (42)
One or more times 42 (15) 42 (37) 31 (22) 31 (58)
Q15 How many times have you used sterilising tablets to clean needles or works in prison in last four weeks?
No of non›respondents 15 3 3 0
Never 229 (85) 71 (63) 112 (80) 26 (49)
One or more times 42 (15) 42 (37) 28 (20) 27 (51)
Q18 Have you ever had an acute attack of hepatitis or yellow jaundice?
No of non›respondents 3 2 4 0
Yes 31 (11) 27 (24) 7 (5) 7 (13)
No 252 (89) 87 (76) 132 (95) 46 (87)
Q19 Have you ever been offered vaccination against hepatitis B?
No of non›respondents 24 11 10 1
Yes, and completed full course of three injections 6 (2) 4 (4) 2 (2) 1 (2)
Yes, but received only one or two injections 3 (1) 1 (1) 2 (2) 2 (4)
Yes, but declined offer 2 (1) 1 (1) 2 (2) 1 (2)
No, never offered 251 (96) 99 (94) 127 (95) 48 (92)
Papers
Regional Virus
Laboratory,
Edinburgh
EH10 5SB
Sheila Burns,
clinical virologist
Correspondence to:
Dr Gore
(sheila.gore@mrc›bsu.
cam.ac.uk)
22 BMJ VOLUME 315 5 JULY 1997
and explained the linkage of questionnaire and saliva
sample by sealed number pair (chosen at random by
the prisoners)2 and that the survey and research team
were unconnected with random mandatory drugs test›
ing (due to be introduced to both prisons in 1997).
Results
The participation rate was 94% (293 of 312 prisoners)
at Lowmoss and 93% (146/157) at Aberdeen (table 1).
Two Lowmoss prisoners (both injectors) tested positive
for HIV antibody. HIV prevalence was 0.7% overall and
1.7% (2/116) for injector inmates. At Aberdeen one
saliva sample was insufficient and two prisoners (both
non›injectors and heterosexual, one known to the
prison’s medical service) were HIV positive; HIV
prevalence was 1.4% (2/145) overall but nil for injector
inmates.
Table 2 gives prisoners’ answers to questions about
injecting, use of sterilising tablets, and uptake of
hepatitis B vaccination for all 286 Lowmoss and 143
Aberdeen participants whose questionnaires passed
logical checks and, separately, for the 116 and 53
injecting drug users (that is, people with a history of
injecting drug use).
Injecting drug users and injecting inside prison
Forty five per cent (52/116) of Lowmoss’s injecting
drug users began their injecting career in 1989 or later
compared with 77% (41/53) of Aberdeen prison’s
injector inmates, 19 of whom had started injecting very
recently (in 1995 or later). Fifty four per cent (61/113)
of Lowmoss’s injecting drug users had injected on the
day of entering prison or the day before, as had 52%
(27/52) of injecting drug users at Aberdeen. Fifty seven
per cent (66/116) of Lowmoss’s injecting drug users
had ever injected inside prison but only five (4%) had
started to inject inside; at Aberdeen these figures were
74% (39/53; P < 0.03) and 19% (10/52; P < 0.01).
Forty two Lowmoss prisoners (15% of all inmates;
37% of injector inmates) and 31 Aberdeen prisoners
(22% of all inmates; 58% of injector inmates) had
injected in prison in the previous four weeks. The
prisons together held 112 injector inmates who had
been in prison for more than four weeks, of whom 57
(51%) had injected in prison in the previous four weeks
as follows: once (10 inmates), two to five times (24),
6›10 times (17), 11›20 times (5), 21›50 times (1); their
estimated mean number of injections in the four weeks
was 6.0 (SD 5.7).
Sterilising tablets and hepatitis B vaccination
Injector inmates’ answers to questions about both
injecting in prison and the use of sterilising tablets to
clean injecting equipment in the past four weeks were
broadly concordant (Lowmoss: estimated 207 injec›
tions and 258 uses of sterilising tablets to clean needles
or works; Aberdeen: estimated 229 injections and 221
uses of sterilising tablets) (table 3). In both prisons local
arrangements satisfactorily allowed prisoners to access
sterilising tablets for the harm reduction purpose
intended.
Only 4% of Lowmoss’s inmates (11/262) and 5% of
inmates of Aberdeen prison (6/133) had ever been
offered vaccination against hepatitis B. The low
reported offer rate is the more surprising because 43%
of convicted prisoners in Lowmoss and Aberdeen
prisons (169/392) had been sentenced for more than
six months and is disappointing in view of the high
rates of clinical hepatitis reported by injector inmates
(20%; 34/167; table 2).
Discussion
Results at Aberdeen prison indicated that local inject›
ing drug use was as prevalent but more recent than in
Glasgow. Injecting behaviour in Aberdeen prison
mirrored that in nearby Perth prison10: 74% of
Aberdeen’s injector inmates had ever injected inside
prison (Perth 85%) and 19% had started to inject inside
prison (Perth 31%). Three fifths of injecting drug users
in Aberdeen prison first injected in 1992 or later and
43% were under 26 years of age.
Use of sterilising tablets
In contrast with England and Wales,11 12 the Scottish
Prison Service has provided sterilising tablets in
accordance with the World Health Organisation’s
recommendations13 since December 1993.14 Prisoners
regularly used these tablets to clean injecting
equipment.
Hepatitis B immunisation
In contrast with almost universal acceptance by prison
officers, at most 5% of the inmates studied had ever
been offered immunisation against hepatitis B.
Similarly low rates were discovered in audit studies in
Oxford and Anglia prisons (J Cassidy, personal
communication) and in over 3500 prisoners in
Victoria, Australia,15 where only 5% of non›immune
prisoners had been immunised. Other studies suggest
that low awareness16 and unwillingness (M Rotliy,
personal communication) contribute to low immunisa›
tion uptake by injecting drug users. Specific resources
need to be allocated to prison medical services, general
practitioners, and drug treatment centres for universal
offering of hepatitis B immunisation to prisoners and
former prisoners as routine.17 18
Frequency of injecting inside prison: implications
for random drugs testing
The combined data showed that 51% (57/112) of
injectors who had been in prison for more than four
weeks had injected in the past four weeks while inside.
Their mean number of injections was 6.0 (SD 5.7). If we
assume that the substance injected remained in the
urine for three days (as occurs with heroin), then these
prisoners would be liable to have a positive result in
Table 3 Frequencies of injecting and of using sterilising tablets among injector
inmates at Lowmoss and Aberdeen
No of times injected in
past four weeks
No of times used sterilising tablets to clean needles or works in prison in
past four weeks
Never Once 2›5 6›10 11›20 21›50
Never 85 3 6 0 1 1
Once 2 5 5 2 1 0
2›5 3 0 20 2 0 0
6›10 1 2 5 13 1 1
11›20 0 0 0 1 2 1
21›50 0 0 0 0 1 0
>50 1 0 0 0 0 0
Data on these questions were missing for four Lowmoss prisoners.
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random mandatory drugs tests on a maximum of 18
days out of 28. If, however, random mandatory drugs
testing did not operate at weekends, as in England and
Wales, and prisoners could organise their injecting
accordingly (for Friday evenings and one Tuesday
and one Wednesday evening, say), then they may
test positive on many fewer days—for example, on
(4 Mondays + (Wednesday + Thursday + Friday) +
(Thursday + Friday)) = 9 days out of 28. On these
assumptions we would expect only two thirds to one
third of prisoners who are injecting heroin inside prison
to test positive in random mandatory drugs tests.
Random mandatory drugs testing is therefore
likely seriously to underestimate prisoners’ injection
related drug use problems. Underestimation will entail
underresourcing of these and other prisons in respect
of the healthcare and drug reduction needs of their
injector inmates.
Obligations to injector inmates
The current extent of injecting among inmates of our
prisons demands that we think again about society’s
obligation to these addicted people. As they continue
to take class A drugs by injection inside prison, we must
enable them to do so more safely. This requires that
ready access to sterilising tablets should be extended to
all prisoners in Britain, not just to those in Scotland. It
also requires that all prisoners who could benefit from
substitute prescribing should receive it, the primary
goal being to help them stop injecting; drug reduction
is a secondary objective. If sterilising tablets are used
suboptimally they may not protect absolutely against
bloodborne virus transmission; hence prisoners, like
other citizens in Britain, need access to various harm
reduction measures. Some are denied methadone, all
are denied needle exchange. Prison needle exchange
has been pioneered in Switzerland,19 is being evaluated
in Germany, and is under consideration in Canada.20
If the current limited access to harm reduction
measures is perpetuated it represents a serious gulf
between the standards of health care and public health
available to the same individuals in prison and outside.
Prison medical service policy promotes equality but is
short on delivery.21
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Key messages
x Half of injector inmates of two Scottish prisons
who had been in prison for more than four
weeks had injected in the previous four
weeks—an average of six times
x Injector inmates used sterilising tablets to clean
injecting equipment as often as they injected
x Only 4% of inmates had ever been offered
vaccination against hepatitis B
x Vaccination against hepatitis B and sterilising
tablets are prisoners’ rights
x Random mandatory drugs testing is likely to
detect only one third to two thirds of heroin
injectors in prison and so seriously
underestimates injector inmates’ drug reduction
needs
Endpiece
Cyril Connolly on obesity
Imprisoned in every fat man a thin one is wildly
signalling to be let out.
Cyril Connolly, The Unquiet Grave (1944)
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Physiotherapy for patients with soft tissue shoulder
disorders: a systematic review of randomised clinical trials
Geert J M G van der Heijden, Daniºlle A W M van der Windt, Andrea F de Winter
Abstract
Objective: To assess the effectiveness of physiotherapy
for patients with soft tissue shoulder disorders.
Design: A systematic computerised literature search
of Medline and Embase, supplemented with citation
tracking, for relevant trials with random allocation
published before 1996.
Subjects: Patients treated with physiotherapy for
disorders of soft tissue of the shoulder.
Main outcome measures: Success rates, mobility,
pain, functional status.
Results: Six of the 20 assessed trials satisfied at least
five of eight validity criteria. Assessment of methods
was often hampered by insufficient information on
various validity criteria, and trials were often flawed by
lack of blinding, high proportions of withdrawals
from treatment, and high proportions of missing
values. Trial sizes were small: only six trials included
intervention groups of more than 25 patients.
Ultrasound therapy, evaluated in six trials, was not
shown to be effective. Four other trials favoured
physiotherapy (laser therapy or manipulation), but the
validity of their methods was unsatisfactory.
Conclusions: There is evidence that ultrasound
therapy is ineffective in the treatment of soft tissue
shoulder disorders. Due to small trial sizes and
unsatisfactory methods, evidence for the effectiveness
of other methods of physiotherapy is inconclusive. For
all methods of treatment, trials were too
heterogeneous with respect to included patients,
index and reference treatments, and follow up to
merit valid statistical pooling. Future studies should
show whether physiotherapy is superior to treatment
with drugs, steroid injections, or a wait and see policy.
Introduction
Pain is the primary symptom in most patients with
shoulder disorders affecting the soft tissue. In many
patients, painful restriction of the range of shoulder
movement limits the ability to perform daily activities.
Estimates of the cumulative annual incidence of
shoulder disorders vary from 7 to 25 per 1000 general
practice consultations.1›3 Five per cent of all general
practice consultations are reported to be related to
shoulder disorders.4 5 Half of all presented episodes
resolve within six months, but some last a year or more.
Most patients with such disorders are treated in
primary care. Their management includes advice,
analgesics, non›steroidal anti›inflammatory drugs,
steroid injections, and physiotherapy. Evidence from
randomised clinical trials on shoulder disorders shows
small effects favouring the effectiveness of non›
steroidal drugs6 and steroid injections.7 A wide array of
physiotherapy methods is used to treat shoulder dis›
orders.8 9
Patients are often referred for physiotherapy10 11; in
the Netherlands as many as a third of all patients with
shoulder disorders are referred.2 3 12 So far, little effort
has been invested in establishing the effectiveness of
management with physiotherapy. We examined
whether certain methods in physiotherapy are effective
for patients with soft tissue shoulder disorders by
reviewing reports of 20 randomised clinical trials.
Methods
Selection of studies
Relevant trial reports were harvested from Medline
(Index Medicus January 1966 to December 1995) and
Embase (Excerpta Medica January 1984 to December
1995) according to the computerised search strategy of
Dickersin et al.13 This strategy was supplemented with
citation tracking of relevant publications. GH identified
trial reports that met the following five conditions:
firstly, patients had shoulder pain at inclusion;
secondly, treatments were allocated by a random
procedure; thirdly, at least one of the treatments
included physiotherapy; fourthly, success rate, pain,
mobility, or functional status were included as outcome
measures; and, finally, results were published as a full
report before January 1996. From this selection DW
and AW independently selected the trials that included
patients with soft tissue shoulder disorders.
Assessment of methods
To assess trial methods, eight criteria for internal
validity were used (box). These criteria are based on
generally accepted requirements of methods for
design and conduct of intervention research.14›17 In
addition, five data display and extraction criteria (box)
were used to provide information on the feasibility of
statistical pooling.18
We independently analysed the completeness of
information from the selected trial reports. For each
criterion we logged whether incomplete information
had hampered the assessment of methods. If sufficient
information was given we judged and logged whether
bias was likely or not. For criteria for which consensus
could not be reached, the presented results are based
on agreement of two reviewers. Subsequently, the trials
were ranked according to the number of validity
criteria for which bias was considered to be unlikely.
Success rates were determined for each inter›
vention group by dividing the number of documented
successes at the end of the intervention period by the
number of patients randomly allocated to the
intervention (that is, intention to treat analysis). When
success rates could not be calculated, we determined
change in scores for pain and mobility ratings. Missing
values for outcome measures were assumed to
represent failures (that is, worst case assumption). Next,
to judge the effectiveness of treatments we calculated
the differences between groups for outcome measures,
with 95% confidence intervals. Finally, to draw con›
clusions we related these confidence intervals to the
number of satisfied validity criteria.
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Results
Study selection
GH identified 47 trial reports that met the five
conditions for further selection. DW and AW excluded
24 trials: seven in which the results of patients who
received physiotherapy for shoulder disorders were
not presented separately, one in which similar
physiotherapy was given as a cointervention to all
patients, four on exercise therapy after mastectomy,
four on physiotherapy for shoulder pain after fracture,
seven on physiotherapy for shoulder pain in hemi›
plegic subjects, and one trial on rheumatoid arthritis.
The methods of the remaining 23 trial reports were
assessed.19›41 Information was combined for three trials
that were reported twice.23 33 40 Hence, the systematic
review included 20 trials on the effectiveness of
physiotherapy for patients with soft tissue shoulder
disorders.
Assessment of methods
Table 1 lists for each trial the validity criteria for which
bias was considered likely. This table also presents the
validity and data display and extraction criteria for
which incomplete information had hampered the
assessment of methods. The trials are ranked
according to the number of validity criteria that were
satisfied. Equally ranked trials are ordered alpha›
betically.
Validity criteria—Eleven of the 20 trials satisfied at
least four of the eight validity criteria. One trial satisfied
all eight19; three other trials satisfied six.20›22 Three trials
seemed to be flawed by a large proportion of
withdrawals from treatment28 31 37; two trials by a large
proportion of missing values26 37; nine trials by
insufficient blinding of intervention25 27 28 31 35›39; and
three trials by a insufficient blinding of outcome assess›
ment.25 30 39 Many reports lacked adequate information
on several validity criteria. The randomisation pro›
cedure was adequately reported for one trial19 and
prognostic status at baseline for four trials19 25 28 30;
information on cointerventions was often insufficient.
Data display and extraction criteria—In general the
sample sizes of the studies were small: six trials com›
pared groups of 25 or more patients25 26 29 33 35 39 and six
trials compared groups of 15 to 25 patients.21 27 28 30 36 40
All other trials included smaller study populations.
Data on outcome measures were poorly reported. Of
the 11 trials with acceptable methods,19›23 25›30 five
provided sufficient data for the calculation of 95% con›
fidence intervals.19 23 25 26 30 Such calculation was
possible for six of the nine remaining trials with
unsatisfactory methods.
Characteristics of trials
Table 2 outlines the study population, intervention,
follow up, and reported results of the assessed trials.
Again, the trials are ordered by the number of fulfilled
validity criteria. In nine trials participation was
restricted to narrowly defined diagnostic categories
(for example, rotator cuff tendinitis),19 20 22 23 25 26 28 30 33
whereas other trials included a wide variety of soft
tissue disorders (for example, painful shoulder, peri›
arthritis humeroscapularis). In eight trials, duration of
symptoms at baseline was not specified as an entry
criterion.23 27›28 30 35 37 38 40 Another eight trials included
patients who, at baseline, had had their symptoms for
less than three months,19 21 22 29 31›33 36 whereas in the
four remaining trials duration of symptoms at baseline
exceeded three months.
Ultrasound therapy was studied in six
trials,19 23 28 29 38 39 different methods of thermotherapy
Validity criteria for assessment of methods of
trials
1 Enrolment—Restriction to a homogeneous
population with respect to prognosis and susceptibility
to allocated interventions by explicit selection criteria.
Used as prognostic indicators: age, duration of
complaint, painful arc, pain at night, number of
relapses, radiating pain, previous treatment
2 Randomisation—Adequate procedure for
generation of random numbers list and concealed
allocation of interventions
3 Similarity at baseline—Similarity of intervention
groups at baseline with respect to prognosis and
susceptibility to allocated interventions. Used as
prognostic indicators: baseline scores for outcome
measures, age, duration of complaint, painful arc, pain
at night, number of relapses, radiating pain, previous
treatment
4 Withdrawals from treatment—No patients
withdrew from treatment or number of patients was
< 10% in each group, with comparable reasons for
withdrawal
5 Missing values (for example, loss to follow
up)—Number of randomised patients minus number
of reported patients at main moment of effect
measurement for main outcome measure—if not
stated according to reviewers—divided by all
randomised patients × 100 was < 10% in each group
6 Cointerventions—Either standardised or excluded
in trial design
7 Blinded application of interventions—Therapists:
blinding by credible placebo. Patients: blinding by
credible placebo or by enrolment of patients who were
naive to allocated interventions
8 Blinded assessment of outcome—Assessor of effect
of variables (for example, patient, therapist, physician,
or research staff) blinded for allocated interventions
Data display and extraction criteria
1 Sample size of groups
2 Standardisation of allocated interventions—
Adequate description of type, method, application of
technique, intensity, duration, number, and frequency
of sessions for all allocated interventions
3 Reported outcome variables—Success rate (for
example, proportion of patients cured or improved);
pain; functional state (activities of daily living); mobility
(range of movement); non›trial cointerventions (for
example, drugs or surgery)
4 Outcome assessments—Identical timing of
assessment for all intervention groups: immediately
after last treatment or over three months
5 Actual data for outcome variables—An adequate
point estimate is presented for each intervention
group (with corresponding distribution measure) for
success rate or improvement for pain or most
important outcome measure on most important
moment of effect measurement
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in three trials,37 38 40 and low level laser therapy in
four trials.22 30 32 33 Three trials concerned magneto›
therapy,20 21 26 three concerned manipulations or mobil›
isations,27 31 36 two trials involved electrotherapy28 35 or
cold therapy,31 39 and one trial evaluated an exercise
programme.25
Six trials compared various methods of physio›
therapy,26 28 31 35 38 39 nine trials compared physio›
therapy with placebo treatment,19 20›22 25 29 30 32 33 and 10
trials compared physiotherapy with another interven›
tion (mainly analgesics, non›steroidal drugs, and
steroid injections).23 25 27 31 32 37›41 Furthermore, two
trials included a control group without any treat›
ment.21 31 Results from long term follow up (at least two
months after randomisation) were available from four
trials.21 25 36 39 Follow up in all other trials was restricted
to assessment of outcome directly after completion of
treatment, usually three or four weeks after random›
isation.
Effectiveness of treatment
The validity of four of the six trials that studied the
effect of ultrasound therapy was acceptable, but none
of these trials showed evidence in its favour.19 23 28 29
Ultrasound therapy was no better than cold therapy
and steroid injections,39 non›steroidal anti›inflam›
matory drugs and acupuncture,23 transcutaneous
electrical stimulation,28 and analgesics and ionto›
phoresis.38 Moreover, ultrasound therapy did not
seem to be effective in placebo controlled trials.19 23 29
The validity of two of the four trials that studied
the effectiveness of low level laser therapy was
acceptable.22 30 Saunders could not find significant
differences between active and placebo laser.22 Our
calculations of the results of Vecchio et al showed very
small differences in favour of active low level laser
therapy, though the authors, using different statistical
methods, did not find significant differences.30 The two
other trials with unsatisfactory methods reported
effects in favour of the short term effectiveness of low
level laser therapy compared with placebo32 33 or with
non›steroidal drugs.32
Transcutaneous electrical stimulation did not seem
to be more effective than ultrasound therapy28 or than
other electrical methods.35 We could not find any
placebo controlled trial on electrotherapy. The two
placebo controlled trials on pulsed electromagnetic
fields had acceptable validity and reported favourable
results for treatment.20 26 The results of Chard et al,
however, were non›significant when they were analysed
according to the intention to treat principle.26 Magnetic
treatment seemed to be ineffective when it was
compared with no treatment.21
Cold therapy was no more effective than ultra›
sound therapy,39 steroid injection,31 39 mobilisations, or
no intervention.31 Different methods of thermotherapy
were not more effective than placebo37 38 or steroid
injections and analgesics.40
Exercises were as effective as surgery in patients
with a stage II impingement syndrome and were more
effective than placebo laser therapy.25 When they were
compared to no intervention,31 36 mobilisations and
manipulations did not contribute to recovery nor were
they superior to steroid injections27 31 or cold therapy.31
Discussion
This systematic review, based on the reports of 20
randomised clinical trials, evaluated whether physio›
therapy contributes to the extent and speed of
recovery for patients with soft tissue shoulder
disorders. It used an assessment of methods to
minimise bias.
Trial methods
The validity of the methods of 11 of the 20 assessed
trials was satisfactory. One trial reported all the
information needed for assessment of validity and data
display and extraction.19 Many trials did not provide
sufficient information for at least two validity criteria.
This poor reporting might hide flaws; thus it hinders
the interpretation of trial results. This lack of
information was most prominent for the randomisa›
tion procedure, baseline similarity of treatment groups,
and cointerventions.
Schulz et al provided empirical evidence of bias for
trials with inadequate concealment of treatment and
lack of blinding.42 Lack of prognostic comparability at
baseline, withdrawals, and missing data are also related
to success of treatment and therefore represent major
sources of bias.43 44
Effectiveness of treatment
Deficiencies in the presentation of data often
hampered calculation of 95% confidence intervals.
When we could calculate confidence intervals they
were wide and included zero, even when trials had
acceptable methods.19 23 26
Few of the assessed trials favoured the effective›
ness of physiotherapy. The type of control treatment
seemed unrelated to the study results. Because there
were many small trials with negative results, statistical
pooling of the results of trials with acceptable
methods would have been useful. However, we consid›
ered that the few valid trials on the same methods of
Table 1 Assessment of methods of trials of physiotherapy for shoulder disorders.
Validity criteria for which bias must be considered likely, and validity and data display
and extraction criteria for which incomplete information hampered assessment.
Numbers refer to points in boxes
First author
Bias considered
likely
Incomplete information for
validity assessment
Incomplete data display
for data extraction
Downing19 — — —
Binder20 — 2,3 5
Leclaire21 — 2,3 —
Saunders22 — 2,3 3
Berry 23; Fernandes24 — 1,2,3 2
Brox25 7,8 2 5
Chard26 5 2,3,6 —
Dacre27 7 2,3,6 2,5
Herrera›Lasso28 4,7 1,2 —
Nykänen29 — 1,2,3,4 —
Vecchio30 — 1,2,4,5 —
Bulgen31 4,7 2,3,6 2,3,5
England32 — 1,2,3,4,6 5
Gudmundsen33; Hartvig34 8 1,2,3,6 —
Knüsel35 — 1,2,3,6,7 3,4,5
Thomas36 7 1,2,3,6,8 —
Biswas37 4,5,7 1,2,3,8 2,3,5
Delacerda38 7 1,2,3,4,6,8 3,4,5
Knorre39 1,7,8 2,3,4,5,6 5
Lee40 41 1,7 2,3,4,5,6,8 3,5
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treatment (for example, ultrasound therapy or low
level laser therapy) were too heterogeneous with
respect to administration (for example, intensity, dura›
tion, and frequency of administration), the compared
treatment (for example, placebo, no treatment, or
alternative control treatment), the selection of study
populations (for example, regarding specific soft tissue
disorders or symptom duration at baseline), and
follow up (for example, timing of outcome assessment
and choice of outcome measures) to merit statistical
pooling.
Given the adequate methods of placebo controlled
trials on ultrasound therapy, this method does not
seem to be effective in treating patients with shoulder
disorders. One placebo controlled trial with adequate
methods reported superior effectiveness of pulsed
electromagnetic fields. All other trials that reported
significant results were small and had unsatisfactory
methods. Thus there is insufficient evidence to draw
conclusions on the effectiveness of low level laser
therapy, heat treatment, cold therapy, electrotherapy,
exercise, and mobilisations.
Table 2 Summary of treatments compared and results of trials of physiotherapy for shoulder disorders
First author Treatments Follow up Result (No in group) % Difference (95%CI)
Downing19 Continuous ultrasound
Placebo ultrasound
All received home exercises
No recovered at 4 weeks 7 (11)
4 (9) 20 (−23 to 63)
Binder20 Pulsed electromagnetic fields
Placebo pulsed electromagnetic fields
No recovered at 4 weeks * (15)
* (14)
Significant differences
Pulsed electromagnetic fields > placebo
Leclaire21 Magnetotherapy
Placebo magnetotherapy
All received heat and exercise
Mean (SD) pain (scale 0›4) at 12 weeks 1.5 (0.6); (22)
1.4 (0.7); (25)
No significant differences
Saunders22 Low level laser
Placebo laser
Pain at 12 weeks * (12)
* (12)
No significant differences
Berry23 Ultrasound
Tolmetin sodium and steroid injection
Placebo tolmetin and steroid injection
Placebo tolmetin and placebo ultrasound
Acupuncture
No recovered at 4 weeks 6 (12)
5 (12)
6 (12)
9 (12)
5 (12)
8 (−32 to 48) v ultrasound
0 (−40 to 40) v ultrasound
−25 (−62 to 12) v ultrasound
8 (−32 to 48) v ultrasound
Brox25 Exercises
Placebo laser
Arthroscopic resection of bursa and acromion
Median pain at 3 months; 6 months 15 (50); 25 (50)
15 (30); 15 (30)
25 (45); 25 (45)
−13 (−20 to −7) v exercises
−5 (−10 to 0); −5 (−10 to 0) v exercises
Chard26 Pulsed electromagnetic fields 8 hours/day
Pulsed electromagnetic fields 2 hours/day
No recovered at 4 weeks; 8 weeks 12 (25); 13 (25)
14 (25); 17 (25) −8 (−36 to 20); −16 (−43 to 11)
Dacre27 Mobilisation
Steroid injection
Mobilisation and steroid injection
Pain at 3 months * (20)
* (22)
* (20)
No significant differences
Herrera›Lasso28 Ultrasound
Transcutaneous electrical stimulation
All received heat and exercise
Pain at 6 weeks * (15)
* (15)
No significant differences
Nykänen29 Pulsed ultrasound
Placebo ultrasound
Mean (SD) pain (scale 1›5) at 4 weeks 2.5 (0.7); (35)
2.4 (0.9); (37)
No significant differences
Vecchio30 Ga›As›Al laser
Placebo laser
All received exercises
Mean (SD) pain at 8 weeks 3.6 (0.9); (19)
1.8 (1.2); (16) 1.8 (1.1 to 2.5)
Bulgen31 Maitland mobilisations
Ice packs; proprioceptive neuromuscular
facilitation exercises
Steroid injection
No treatment
All received medication and pendular exercises
Pain at 3 months * (11)
* (12)
* (11)
* (8)
No significant differences
England32 Infrared laser
Placebo laser
Naproxen tablets
Median pain reduction at 2 weeks * (10)
* (10)
* (10)
2.5 (2 to 3) v laser
2 (1 to 3.5) v laser
Gudmundsen33 Ga›As laser
Placebo laser
No recovered at 1 month 42 (47)
18 (44) 48 (31 to 65)
Knüsel35 Transcutaneous electrical stimulation constant
current
Constant voltage electrotherapy
No recovered at 3 weeks 19 (30)
21 (30) 7 (−15 to 29)
Thomas36 Forced manipulation
No manipulation
All received hydrocortisone injection
No recovered at 3 months 12 (15)
7 (15) 33 (1 to 65)
Biwas37 Diathermy
Hydrocortisone injection
Aspirin
All received exercises
No recovered at 3 months 8 (17+n)
9 (18+n)
7 (12+n)
Size of group after randomisation unclear; 47
of 120 randomised patients reported
Delacerda38 Continuous ultrasound and thermotherapy
Dexamethasone iontophorese
Analgesics and muscle relaxants
No recovered at 4 weeks 6 (8)
8 (8)
4 (7)
25 (−5 to 35) v ultrasound
18 (−29 to 65) v ultrasound
43 (6 to 80) v iontophorese 2
Knorre39 Ultrasound
Ice
Triamcinolone injection
No recovered at 2 weeks; 12 weeks 14 (30); 15 (30)
15 (30); 15 (30)
12 (30); 11 (30)
10 (−15 to 35) v ultrasound
3 (−22 to 28) v ultrasound
Lee40 Infrared heat; exercises
Hydrocortisone intra›articular injection;
exercises
Hydrocortisone tendon injection; exercises
Analgesics
Pain at 6 weeks * (17)
* (15)
* (18)
* (15)
No significant differences
*Data displayed graphically, no actual data presented.
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The purpose of treating patients with shoulder dis›
orders is to increase the extent and speed of recovery.
As ultrasound therapy is not effective, any further
application in patients with shoulder disorders should
be discouraged. This can be done by updating
treatment guidelines or by withholding reimbursement
for its use.
Future trials should show whether other methods
of physiotherapy for shoulder disorders are effective.
This should be particularly interesting for exercise and
mobilisations, which have rarely been subjected to
scientific scrutiny in randomised clinical trials despite
being commonly used in patients with shoulder dis›
orders. Priority should be given to a comparison of
exercise and mobilisations with analgesics and advice
and a wait and see policy. As there are some indications
for their effectiveness, steroid injections and non›
steroidal drugs are other relevant comparative
treatments. During the design and execution of future
trials specific attention should be given to the control
of prevalent flaws, such as many withdrawals, many
missing results, and a lack of blinding during treatment
and assessment of outcome. Standards of reporting tri›
als should prevent confusion about the validity of trial
methods and ensure adequate data analysis and
presentation of pertinent data.16 45
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Prevalence of HIV and injecting drug use in men entering
Liverpool prison
Mark A Bellis, Andrew R Weild, Nick J Beeching, Ken J Mutton, Qutub Syed
Studies in countries other than England and Wales
suggest that a comparatively high proportion of
people entering prison have a history of injecting drug
use before imprisonment and that drug use does not
always stop once people are incarcerated.1 Con›
sequently the sharing of injecting equipment by drug
users in a Scottish prison led to the infection of at least
13 inmates with HIV.2 Currently, little information is
available on the number of drug users entering prisons
in England and Wales, their HIV prevalence, or their
levels of injecting drug use once incarcerated.
Therefore, discussion about the potential for injecting
related HIV transmission within these prisons often
requires extrapolation from data gathered in other
countries.3 To examine the potential role of English
prisons in drug related transmission of HIV and other
bloodborne viruses we administered questionnaires to
new prisoners at a large men’s prison and tested them
for HIV antibodies.
Subjects, methods, and results
We defined new prisoners as men arriving at prison for
the first occasion relating to their current remand
(that is, awaiting trial or sentencing) or sentence. Over
10 weeks in early 1996, 969 such prisoners at reception
to HM prison, Liverpool, were asked to complete a
short, anonymous questionnaire on their drug related
and sexual behaviour and provide a saliva sample.4
Though participation was voluntary, compliance was
high—921 (95.0%) subjects completed all or part of the
questionnaire and 905 (93.4%) provided a matched
saliva sample, of which one tested positive. Most
participants (881/906; 97.2%) originated within the
British Isles, and ages ranged from 21 to 70 years
(median 28), 63.2% (577/913) of subjects being aged
30 or under. Prisoners on remand accounted for
43.2% (396/916) of the sample. Previously 47.2.%
(416/882) of subjects had been incarcerated before the
age of 21 and 66.8% (588/880) had been in an adult
prison.
Comment
Of 219 subjects with a history of injecting drugs and
incarceration, only 36 (16.4%; table 1) had ever injected
in prison. Though this suggests that imprisonment
reduces injecting behaviour, for those who continue to
inject while incarcerated levels of risk behaviour are
substantially increased. Thus the prevalence of ever
sharing injecting equipment rose from 31.5% (82/260)
among all new arrivals with a history of injecting to
55.6% (20/36) sharing when injecting while incar›
cerated (÷2 = 8.08; P < 0.005). Furthermore, men who
had ever injected as well as current injectors (that is,
those who had injected in the past month) were
disproportionately represented among those return›
ing for second (26.0% ever, 19.7% current) or further
sentences (42.0% ever, 29.9% current). Consequently,
incarceration may reduce the numbers of subjects
injecting drugs but only at the cost of increasing the
risks of infection among those who inject while
imprisoned and without necessarily preventing relapse
into injecting on release.
Of roughly 7000 men received into HM prison,
Liverpool, every year, over a quarter (table 1) may pre›
viously have injected drugs. In this survey only one
such subject was HIV positive (an injecting drug user
currently unaware of his infection), reflecting low levels
of HIV in the local injecting communities.5 However,
the frequent exchange of subjects between such
communities and the prison population means that
drug use in prison cannot be taken in isolation. Indeed,
prisons represent a valuable opportunity to educate
drug users, familiarising them with safe injecting prac›
tice and the range of health services (community drugs
teams, syringe exchange schemes) available, if not
when incarcerated then certainly on release. Alterna›
tively, if levels of HIV or other bloodborne viruses
increase outside prison the high levels of sharing that
occur when drugs are injected in prison may multiply
Table 1 Summary of injecting drug use behaviour by new
arrivals at HM prison, Liverpool. Figures are numbers
(percentages) of subjects
Injecting drug use behaviour Yes
Ever injected drugs 260/911 (28.5)
Shared injecting equipment 82/260 (31.5)
Injected recently (in past month) 177/260 (68.1)
Injected in prison 36/219†(16.4)
Shared injecting equipment in prison 20/36 (55.6)
First injected in prison 8/36 (22.2)
†219 represents injectors who had previous spells in prison.
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numbers of infections and redistribute these among
different drug using groups when inmates are
released.
We are grateful for the support of Cathy James, Mike Jenkins,
Norman Tucker, and Robert Lyons from Liverpool prison and
to the Home Office for permitting this study, the prison inmates
for participating, and Sheila Gore and Graham Bird for advice.
Funding: North West Regional Health Authority.
Conflict of interest: None.
1 Ford BT, Derrickson J. AIDS in prison: a review of epidemiology and pre›
ventive policy. AIDS 1992;6:623›8.
2 Yirrell DL, Robertson P, Goldberg DJ, McMenamin J, Cameron S, Leigh
Brown AJ. Molecular investigation into outbreak of HIV in a Scottish
prison. BMJ 1997;314:1446›50.
3 Curtis SP, Edwards A. HIV in UK prisons: a review of seroprevalence,
transmission and patterns of risk. Int J STD AIDS 1995;6:387›91.
4 Johnson AM, Parry JV, Best SJ, Smith AM, DeSilva M, Mortimer P. HIV
surveillance by testing saliva. AIDS 1988;2:369›71.
5 Morrison CL, Ruben SM. The development of healthcare services for
drug misusers and prostitutes. Postgrad Med J 1995;71:593›7.
(Accepted 21 May 1997)
Drug points
Severe hypotension associated with netilmicin
treatment
T Rygnestad, Department of Anaesthesiology, Regional and
University Hospital, Trondheim, Norway
Cardiovascular side effects from aminoglycosides are
rarely reported,1 which might be the result of under›
reporting. I report a case of severe hypotension associated
with netilmicin treatment in a critically ill patient.
A 50 year old woman with pharyngeal cancer had an
emergency tracheotomy. At operation she had no other
known disease. She developed pneumonia and was
artificially ventilated. Streptococcus milleri was found in
cultures from the operation wound. She was given
netilmicin 140 mg twice daily and metronidazole 500 mg
and cefuroxime 1.5 g three times daily.
From the third postoperative day she had short
hypotensive episodes lasting 5›10 minutes. Her systolic
blood pressure measured in an intra›arterial line fell from
110›120 mm Hg to 60›80 mm Hg, which was accompanied
by a fall in peripheral oxygen saturation on pulse oximetry
of about 5›8%. However, she did not develop reflex tachy›
cardia or show electrocardiographic changes or changes in
central venous pressure. Vascular resistance was not
measured. Her cardiovascular condition deteriorated and
an infusion of dopamine (8 ìg/kg/minute) was started to
increase cardiac contractility. The hypotensive episodes
came immediately after the slow injection of netilmicin was
started and lasted until about five minutes after it had
finished. The same was observed when the regimen was
changed to netilmicin 350 mg once daily, when the netilm›
icin was given as a slow intravenous infusion, and when it
was given intravenously as three equal doses 10 minutes
apart.
The antibiotic regimen was continued because the epi›
sodes were short and diuresis was adequate. Creatinine
clearance was normal and stable. Netilmicin concentrations
were within the recommended range. From the 14th
postoperative day sedation was stopped. She no longer
needed dopamine and the hypotensive episodes almost dis›
appeared. She gradually recovered and had normal kidney
function one week after discharge from intensive care.
This patient developed side effects when she was criti›
cally ill. In critically ill patients—for example, those with
sepsis—many factors might cause hypotension. Side
effects of netilmicin treatment might act in addition to fac›
tors such as septicaemia and heavy sedation. The lack of
reflex tachycardia suggests a direct cardiodepressive effect.
A direct vascular effect cannot be ruled out.
1 Keller H, Maurer P, Blaser J, Follath F. Miscellaneous antibiotics. In: Dukes
MNG, ed. Meyler’s side effects of drugs. 12th ed. Amsterdam: Elsevier, 1992:
637›71.
Simvastatin and impotence
G Jackson, Cardiac Department, Guy’s Hospital, London SE1 9RT
The benefits of lowering raised cholesterol concentrations
are established in patients with documented coronary
artery disease and those at high risk.1 2 Inhibitors
of 3›hydroxy›3›methylglutaryl coenzyme A reductase
(statins) are highly effective agents with few reported
adverse effects. However, as their use becomes more
common, adverse effects may be increasingly recognised.
Impotence, rarely volunteered or asked about, is an
important adverse effect of drugs and not currently
associated with simvastatin.
Five men with coronary artery disease developed
impotence within one week of starting treatment with
simvastatin 10 mg or having the dose increased to 20 mg
(three men); they also had profound lethargy and inertia.
Drug treatment for heart disease (aspirin alone in two
patients) was not changed. Within one week of stopping
simvastatin sexual function was restored. Two patients
were rechallenged with simvastatin and impotence
recurred and was resolved within a week. Alternative lipid
lowering drugs (fluvastatin in four patients and fenofibrate
in one) maintained similar degrees of reduction in
cholesterol concentration and no sexual difficulties over
12›36 months of follow up.
Adverse effects on sexual function are not reported in
the major trials of simvastatin or in the drug’s data sheets.
The Australian Adverse Drug Reactions Committee has
reported 42 cases of impotence associated with simvastatin,
the onset being from 48 hours to 27 months after starting
treatment.3 Simvastatin was the only drug implicated in 35
cases, with four developing impotence on rechallenge.
Simvastatin may affect the central nervous system
directly by passing through the blood›brain barrier or it
may interact with other agents that might cause
impotence. However, two of these five patients and 35 in
Australia were not receiving any other drugs, which
suggests an effect on the central nervous system.
Adverse effects on sexual function due to simvastatin
are infrequent and should not detract from the strong evi›
dence of the drug’s effectiveness in reducing cardiac
events. However, as the use of statins increases such
individual problems may arise, and early recognition may
lead to their alleviation. Furthermore, the benefits of low›
ering lipid concentrations can be maintained with alterna›
tive agents that may avoid impotence.
1 Scandinavian Simvastatin Study Group. Randomised trial of cholesterol
lowering in 4444 patients with coronary heart disease: the Scandinavian
Simvastatin Survival Study (4S). Lancet 1994;344:1383›9.
2 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW,
et al, for the West of Scotland Coronary Prevention Study Group. Preven›
tion of coronary heart disease with pravastatin in men with hyper›
cholesterolemia. N Engl J Med 1995;333:1301›7.
3 Boyd IW. Comment: HMG›CoA reductase inhibitor›induced impotence.
Ann Pharmacother 1996;30:1199.
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